Loading quotes...
Forecast
The analysts' average price target is €380.53 (+8.20%). The median is €378.36 (+7.58%).
| Buy |
14 |
| Hold |
2 |
| Sell |
1 |
News Go to news feed
West Pharmaceutical Services raises full-year outlook after strong organic revenue
At the Wells Fargo healthcare conference, West Pharmaceutical Services raised its forecast for 2026 organic revenue growth from 7–9% to 10–11%, supported by organic growth in the second quarter that exceeded expectations by $35 million. HVP components are driving growth and now represent more than half of revenue; Annex-1 projects, biologics and GLP-1 programs offer multi-year opportunities. Margin expansion was improved to around 200–250 basis points for the year, while the West Vantage business is being temporarily weighed down by a cyberattack and the expiration of a CGM contract. West plans roughly $250 million in CAPEX, is focused on HVP investments, remains active in share repurchases and sees further growth potential in the Asia-Pacific region and in generics/biosimilars. » More on de.investing.com
West Pharmaceutical hits record high after strong Q2 results and raised full-year guidance
West Pharmaceutical surprised in the second quarter with adjusted earnings per share of $2.37 (expectation $2.08) and revenue of $872.3 million (expectation $839.75 million, +13.8% year‑on‑year). Management raised the full‑year adjusted EPS guidance to $8.85–9.05, well above the consensus of $8.62. The outlook for the third quarter also beat analysts' expectations, pushing the stock in premarket trading to a new yearly high. » More on de.investing.com
West Pharmaceutical completes sale of SmartDose 3.5‑mL system
West Pharmaceutical has completed the sale and transfer of manufacturing and supply rights and the associated facilities for the SmartDose 3.5‑mL on‑body delivery system. The company will continue development and production of other SmartDose versions, including the SmartDose 10‑mL system designed for larger volumes. West operates 50 sites worldwide, reported net sales of USD 3.07 billion for 2025, and its stock trades near its 52‑week high; analysts point to a high P/E ratio of 48.5. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 772.05M | 12.65% |
| Gross profit | 306.7M | 22.63% |
| Net profit | 188.93M | 58.37% |
| EBITDA | 276.86M | 49.66% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €24.34B |
Number of shares | 69.66M |
52-week high/low | €390.18 - €199.27 |
Dividend yield | 0.21% |
Dividends TTM | €0.75 |
Next dividend | €0.23 |
Beta | 1.13 |
P/E ratio | 43.75 |
PEG ratio | 1.36 |
P/B ratio | 9.31 |
P/S ratio | 8.05 |
Company profile
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
| Name | West Pharmaceutic.Services |
| CEO | Michel Lagarde |
| Headquarters | Exton,
pa USA |
| Website | |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| IPO | 03/17/1980 |
| Employees | 10,800 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | WST |
Frankfurt | WPS.F |
Düsseldorf | WPS.DU |
SIX | WPS.SW |
München | WPS.MU |
London | 0ADY.L |